Good morning. Elizabeth Cooney here again, subbing for the vacationing Ed Silverman as the week really gets going. Let’s have some news with our coffee.

A Covid-19 vaccine being developed by Oxford University and the drug giant AstraZeneca (AZN) generated an immune response in a study of roughly 1,000 patients, according to interim results, the first glimpse researchers have gotten at its efficacy, STAT reports. The data show a relatively safe vaccine, although side effects were greater than for a meningitis vaccine to which it was compared. AstraZeneca said it is likely that future studies will test giving patients two doses of the vaccine.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy